Chronic Brucella Infection Induces Selective and Persistent Interferon Gamma-Dependent Alterations of Marginal Zone Macrophages in the Spleen

Infect Immun. 2017 Oct 18;85(11):e00115-17. doi: 10.1128/IAI.00115-17. Print 2017 Nov.

Abstract

The spleen is known as an important filter for blood-borne pathogens that are trapped by specialized macrophages in the marginal zone (MZ): the CD209+ MZ macrophages (MZMs) and the CD169+ marginal metallophilic macrophages (MMMs). Acute systemic infection strongly impacts MZ populations and the location of T and B lymphocytes. This phenomenon has been linked to reduced chemokine secretion by stromal cells. Brucella spp. are the causative agent of brucellosis, a widespread zoonotic disease. Here, we used Brucella melitensis infection as a model to investigate the impact of chronic stealth infection on splenic MZ macrophage populations. During the late phase of Brucella infection, we observed a loss of both MZMs and MMMs, with a durable disappearance of MZMs, leading to a reduction of the ability of the spleen to take up soluble antigens, beads, and unrelated bacteria. This effect appears to be selective as every other lymphoid and myeloid population analyzed increased during infection, which was also observed following Brucella abortus and Brucella suis infection. Comparison of wild-type and deficient mice suggested that MZ macrophage population loss is dependent on interferon gamma (IFN-γ) receptor but independent of T cells or tumor necrosis factor alpha receptor 1 (TNF-αR1) signaling pathways and is not correlated to an alteration of CCL19, CCL21, and CXCL13 chemokine mRNA expression. Our results suggest that MZ macrophage populations are particularly sensitive to persistent low-level IFN-γ-mediated inflammation and that Brucella infection could reduce the ability of the spleen to perform certain MZM- and MMM-dependent tasks, such as antigen delivery to lymphocytes and control of systemic infection.

Keywords: Brucella melitensis; brucellosis; infection; low-grade Th1 inflammation; marginal zone macrophages; spleen.

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology
  • B-Lymphocytes / immunology
  • B-Lymphocytes / microbiology
  • Brucella abortus / drug effects
  • Brucella abortus / immunology
  • Brucella abortus / pathogenicity
  • Brucella melitensis / drug effects
  • Brucella melitensis / immunology
  • Brucella melitensis / pathogenicity
  • Brucella suis / drug effects
  • Brucella suis / immunology
  • Brucella suis / pathogenicity
  • Brucellosis / drug therapy
  • Brucellosis / genetics
  • Brucellosis / immunology*
  • Brucellosis / microbiology
  • Chemokine CCL19 / genetics
  • Chemokine CCL19 / immunology
  • Chemokine CCL21 / genetics
  • Chemokine CCL21 / immunology
  • Chemokine CXCL13 / genetics
  • Chemokine CXCL13 / immunology
  • Chronic Disease
  • Gene Expression Regulation
  • Host-Pathogen Interactions*
  • Interferon gamma Receptor
  • Interferon-gamma / genetics
  • Interferon-gamma / immunology*
  • Macrophages / immunology*
  • Macrophages / microbiology
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • RNA, Messenger / genetics
  • RNA, Messenger / immunology
  • Receptors, Interferon / deficiency
  • Receptors, Interferon / genetics
  • Receptors, Interferon / immunology*
  • Receptors, Tumor Necrosis Factor, Type I / deficiency
  • Receptors, Tumor Necrosis Factor, Type I / genetics
  • Receptors, Tumor Necrosis Factor, Type I / immunology
  • Rifampin / pharmacology
  • Signal Transduction
  • Spleen / immunology*
  • Spleen / microbiology
  • Streptomycin / pharmacology
  • T-Lymphocytes / immunology
  • T-Lymphocytes / microbiology

Substances

  • Anti-Bacterial Agents
  • Ccl19 protein, mouse
  • Chemokine CCL19
  • Chemokine CCL21
  • Chemokine CXCL13
  • Cxcl13 protein, mouse
  • RNA, Messenger
  • Receptors, Interferon
  • Receptors, Tumor Necrosis Factor, Type I
  • Interferon-gamma
  • Rifampin
  • Streptomycin